The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-04. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
=== Simplifications === In case of conservative body forces, ∇ × B = 0. For a barotropic fluid, ∇ρ × ∇p = 0. This is also true for a constant density fluid (including incompressible fluid) where ∇ρ = 0. Note that this is not the same as an incompressible flow, for which the barotropic term cannot be neglected. This note seems to be talking about the fact that conservation of momentum says
== First round proper == The first round saw the 32 winners from the fourth qualifying round joined by the 48 clubs from League One and League Two. The draw was made on 17 October 2022 by Dion Dublin and Alan Smith on BBC Two, during a live broadcast from Alvechurch. The round included six teams from the seventh tier, the lowest-ranked teams remaining in the competition: Alvechurch, Bracknell Town, Coalville Town, Merthyr Town, Needham Market, and South Shields.
=== Pseudobulbar affect === Pseudobulbar affect (PBA) is a condition involving episodic uncontrollable laughter or crying. PBA mostly occurs in people with neurological injuries affecting how the brain controls emotions. Scientists believe PBA results from prefrontal cortex damage. PBA often involves crying. Hence, PBA is mistakable for depression. But PBA is neurological; depression is psychological. Patients with PBA do not experience typical depression symptoms like sleep disturbances or appetite loss.
Sources: en.wikipedia.org
Valsartan/hydrochlorothiazide, sold under the brand name Diovan HCT among others, is a medication used to treat high blood pressure when valsartan is not sufficient. It is a combination of valsartan, an angiotensin receptor blocker with hydrochlorothiazide, a diuretic. It is taken by mouth. Common side effects include dizziness and headaches. Serious side effects may include allergic reactions, electrolyte abnormalities, and glaucoma. Use in pregnancy is not recommended. The combination was approved for medical use in the United States in 1998. It is available as a generic medication. In 2021, it was the 224th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
=== July === 1 July – First Minister Humza Yousaf announces that the SNP has changed the way it records donations after the issue was highlighted by its auditors. Having previously only kept online records of donations under £250, the party will now keep documented records of the donations. 2 July – During an appearance on BBC Radio Scotland's The Sunday Show, Conservative MSP Jamie Greene alleges that he lost his post in the Shadow Cabinet of Douglas Ross for supporting the Scottish Government's controversial Gender Recognition Reform Bill. 3 July ScotRail train fares are increased by 4.8%. Members of Orkney Islands Council, a Council area of Scotland, vote 15–6 in favour of investigating alternative methods of government that includes the potential to become a crown dependency of the UK or a self-governing territory of Norway. 5 July King Charles III is presented with the Honours of Scotland during a ceremony held at Edinburgh's St Giles Cathedral. SNP MP Angus McNeil is suspended from the party for a week following an argument with the party's chief whip, Brendan O'Hara, after he allegedly threatened O'Hara. 6 July The Scottish and UK governments confirm plans to collaborate on new legislation to prevent landlords excluding parents and people on benefits from renting properties. The 2023 Tiree Music Festival is cancelled a day before events are due to begin due to "extreme weather". 7 July The Scottish Government urges Westminster to decriminalise the personal possession of all illegal drugs, and puts forward a number of proposals for the managed use of drugs.
Each component interacts with the stationary phase in a different manner depending upon its polarity and hydrophobicity. In reverse phase HPLC, the solute with the greatest polarity will interact less with the stationary phase and spend more time in the mobile phase. As the polarity of the components decreases, the time spent in the column increases. Thus, a separation of components is achieved based on polarity. The addition of micelles to the mobile phase introduces a third phase into which the solutes may partition.
Following Rollins' discovery in 1920 that lead aprons protected against X-rays, lead aprons with a lead thickness of 0.5 mm were introduced. Due to their weight, lead-free and lead-reduced aprons were subsequently developed. In 2005, it was recognized that in some cases the protection was significantly less than wearing lead aprons. The lead-free aprons contain tin, antimony and barium, which have the property of producing intense radiation (X-ray fluorescence radiation) when irradiated. In Germany, the Radiology Standards Committee has taken up the issue and introduced a German standard (DIN 6857-1) in 2009. The international standard IEC 61331-3:2014 was finally published in 2014. Protective aprons that do not comply with DIN 6857-1 of 2009 or the new IEC 61331-1 of 2014 may result in higher exposures. There are two classes of lead equivalency classes: 0.25 mm and 0.35 mm. The manufacturer must specify the area weight in kg/m2 at which the protective effect of a pure lead apron of 0.25 or 0.35 mm Pb is achieved. The protective effect of an apron shall be appropriate to the energy range used, up to 110 kV for low energy aprons and up to 150 kV for high energy aprons. If necessary, lead glass panels must also be used, with the front panels having a lead equivalent of 0.5-1.0 mm, depending on the application, and the side shields having a lead equivalent of 0.5-0.75 mm. Outside the useful beam, radiation exposure is primarily caused by scattered radiation from the tissue being scanned.
Sources: en.wikipedia.org
=== Pharmacodynamics === Osemozotan acts as an agonist of the serotonin 5-HT1A receptor. It binds with almost 1,000 times greater affinity for the 5-HT1A receptor than for most other serotonin, dopamine, or adrenergic receptors. Even with repeated exposure of 5-HT1A receptors to osemozotan, there is no change in the number of receptors, unlike with other pharmaceutical agonists. It has been proposed that osemozotan could be used as an analgesic agent because of its activation of 5-HT1A receptors associated with an inhibitory serotonin-signaling pathway within the spinal cord which causes hypoalgesia and decreasing mechanical allodynia. Osemozotan was found to decrease the incidence of fighting in mice similar to buspirone, diazepam, and tandospirone but required a lower pharmacologic dose to produce beneficial effects. Osemozotan showed dose-dependent anti-aggressive effects and was not shown to decrease motor coordination in the mice. When stimulated, 5-HT1A receptors are shown to have anxiolytic and antidepressant pharmacologic effects. OCD patients have been found to have increased 5-HT levels in the brain. With the use of osemozotan as a 5-HT1A agonist, there is a decrease in serotonergic activity in the brain, leading to possible anti-obsessional pharmacological action. One animal mouse model used to test for OCD is known as the marble burying test, in which the amount of marbles buried within a certain time frame is recorded. Mice performed the marble burying test both with and without osemozotan.
=== Genetic mechanisms === In eukaryotes, unlike in prokaryotes, the mechanisms for transcribing DNA into RNA, and then for translating the RNA into proteins, were separated, permitting extensive RNA processing and allowing the expression of genes to become more complex. It had mechanisms for reshuffling its genetic material, and possibly for manipulating its own evolvability. All of these gave the LECA "a compelling cohort of selective advantages".
=== Raman spectroscopy === Raman spectroscopy is a spectroscopic technique that provides non-destructive analysis capable of identifying components within mixtures with chemical specificity without complex sample preparation. Raman spectroscopy relies on photon scattering following visible light radiation, where the shift in photon energies corresponds to information about the system's vibrational modes and their frequencies. Upon obtaining vibrational modenfrequencies, qualitative classifications about the system can be both made and reinforced. Raman spectroscopy works well in parallel with microfluidic devices for many qualitative biological applications. For some applications, Raman spectroscopy is preferred over other detection methods such as infrared (IR) spectroscopy as water has a strong interference signal with IR but not with Raman. Likewise, methods such as high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR), mass spectrometry (MS), or gas chromatography (GC) are also not ideal as these methods require larger sample sizes. Since microfluidics enables experiments with small volumes (including analysis of single cells or few cells), Raman is a leading microfluidic detection method. Specifically, Raman integration with microfluidic devices has strong applications in systems where lipid identification is necessary, common in biofuel research. For example, a lipid fluorescent assay is not selective enough and thus cannot identify molecular differences the way Raman can through molecular vibrations.
The rate of detoxification of alcohol can also be slowed by certain drugs which interfere with the action of alcohol dehydrogenases, notably aspirin, furfural (which may be found in fusel alcohol), fumes of certain solvents, many heavy metals, and some pyrazole compounds. Also suspected of having this effect are cimetidine, ranitidine, and acetaminophen (paracetamol). An "abnormal" liver with conditions such as hepatitis, cirrhosis, gall bladder disease, and cancer is likely to result in a slower rate of metabolism. People under 25 and women may process alcohol more slowly. Food such as fructose can increase the rate of alcohol metabolism. The effect can vary significantly from person to person, but a 100 g dose of fructose has been shown to increase alcohol metabolism by an average of 80%. In people with proteinuria and hematuria, fructose can cause falsely high BAC readings, due to kidney-liver metabolism.
=== 22 February === The SAF and the Sudan Shield Forces claimed to have forced the RSF to retreat from the Soba neighbourhood of eastern Khartoum and retook the Al-Lulua and Al-Samra neighbourhoods southeast of the Soba Bridge connecting Khartoum's southern and eastern neighbourhoods with the rural areas of East Nile, adding that the 17 RSF militants were killed while nine vehicles were destroyed or captured.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.